Other languages Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
3.26 ^USD	+1.24%		-5.92%	+38.72%

Apr. 23	Lixte Biotechnology Files Up to $50 Million Mixed Shelf	MT
Mar. 27	Sector Update: Health Care Stocks Advance Late Afternoon	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lixte Biotechnology Files Up to $50 Million Mixed Shelf	Apr. 23
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 27
Top Midday Gainers	Mar. 27
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	Mar. 27
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	Mar. 21
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	Feb. 26
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	Jan. 29
Top Premarket Decliners	Nov. 28
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Lixte Biotechnology Extends Partnership With Netherlands Cancer Institute, Oncode Institute for Cancer Therapies Investigation	23-10-16
Lixte Biotechnology Names Bas van der Baan as Chief Executive	23-09-26
Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes	23-09-26
Lixte Biotechnology Holdings, Inc. Announces Executive Changes	23-09-26
LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE?s First-in-Class PP2A Inhibitor, LB-100, Plus GSK?s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer	23-09-20
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
LIXTE Biotechnology Closes $3.5 Million Registered Direct Offering, Private Placement	23-07-21
Top Midday Decliners	23-07-18
LIXTE BIOTECHNOLOGY SHARES FALL 26% AFTER $3.5 MLN SHARE OFFERIN…	23-07-18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Other languages

Filters